Enbiosis Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
22
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$1.5M
- Investors
-
5
Enbiosis General Information
Description
Developer of an artificial intelligence algorithm analyzing biotechnology intended to improve the quality of human health. The company's technology specializes in combining artificial intelligence and microbiome science to analyze the human gut microbiome to provide personalized health guidance, which covers a diet program and prebiotics, enabling people to reach deep into their inner world with the microbiome and stay healthy with diet.
Contact Information
Website
www.enbiosis.comCorporate Office
- 25 Cabot Square
- London E14 4QZ
- England, United Kingdom
Corporate Office
- 25 Cabot Square
- London E14 4QZ
- England, United Kingdom
Enbiosis Timeline
Enbiosis Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC | 22-Jan-2024 | $1.5M | Completed | Generating Revenue | ||
| 3. Accelerator/Incubator | 01-May-2023 | Completed | Generating Revenue | |||
| 2. Accelerator/Incubator | Completed | Generating Revenue | ||||
| 1. Early Stage VC | 04-Jan-2021 | Completed | Generating Revenue |
Enbiosis Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Class B | ||||||||
| Class A | ||||||||
| Class B | ||||||||
| Class A | ||||||||
| Class B | 4,766 | $0.001000 | $18.17 | $18.17 | 1x | $18.17 | 10.43% | |
| Class B | 21,200 | $0.001000 | $17.62 | $17.62 | 1x | $17.62 | 46.39% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Enbiosis Patents
Enbiosis Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4309662-A1 | Microorganisms converting inositol to butyrate | Inactive | 19-Jul-2022 | ||
| US-20240026310-A1 | Microorganisms converting inositol to butyrate | Inactive | 19-Jul-2022 | ||
| EP-4309663-A1 | Microorganisms synthesizing anti-inflammatory molecules | Inactive | 19-Jul-2022 | ||
| US-20240024376-A1 | Microorganisms synthesizing anti-inflammatory molecules | Pending | 19-Jul-2022 | A61K35/74 |
Enbiosis Signals
Enbiosis Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| QInvest Portfoy Yonetimi | Asset Manager | Minority | ||
| Tech Ventures | Venture Capital | Minority | ||
| Grow London | Accelerator/Incubator | |||
| Pragma Capital Partners | PE/Buyout | Minority | ||
| Yapay Zeka Fabrikasi | Corporate Venture Capital | Minority |
Enbiosis FAQs
-
When was Enbiosis founded?
Enbiosis was founded in 2019.
-
Where is Enbiosis headquartered?
Enbiosis is headquartered in London, United Kingdom.
-
What is the size of Enbiosis?
Enbiosis has 22 total employees.
-
What industry is Enbiosis in?
Enbiosis’s primary industry is Other Healthcare Technology Systems.
-
Is Enbiosis a private or public company?
Enbiosis is a Private company.
-
What is the current valuation of Enbiosis?
The current valuation of Enbiosis is .
-
What is Enbiosis’s current revenue?
The current revenue for Enbiosis is .
-
How much funding has Enbiosis raised over time?
Enbiosis has raised $1.5M.
-
Who are Enbiosis’s investors?
QInvest Portfoy Yonetimi, Tech Ventures, Grow London, Pragma Capital Partners, and Yapay Zeka Fabrikasi have invested in Enbiosis.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process